⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 15, 2024Open Access

Supplementary Figure S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer

Yinu Wang Xiaolei Situ Horacio Cárdenas Ellie Siu Sayedabdulrazzaq A. Alhunayan Russell Keathley Edward J. Tanner Jian‐Jun Wei Yuying Tan Chinmayee Vallabh Prabhu Dessai Ji‐Xin Cheng Daniela Matei

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

OC cells are highly sensitive to NTX301 treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e73ec2b6db6435876b817b https://doi.org/10.1158/1078-0432.25415442.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024
2Supplementary Figure S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024
3Supplementary Figure S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024
4Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024
5Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024

More related papers

Supplementary Material and Methods S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024
Supplementary Material and Methods S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024
Data from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer2024